Purple Biotech Ltd. (PPBT)

Nasdaq: PPBT · Pharmaceutical Preparations · Rehovot, IL · filing with the SEC since 2014

Full chart Alerts Compare

Grade4.7

◀ Past 6.1● Present 3.9▶ Future 4.4

3 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Purple Biotech Ltd.

Nine metrics read from its own filings, by tense

Headline grade

4.7/10

◀ Past6.125% of the headline

● Present3.935% of the headline

▶ Future4.440% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

6.1/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

8.2/10

Has it survived what it has been through?

No warning events in its filings since 2017.

weight 22% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

Purple Biotech Ltd.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

9.3/10

What has it actually done, year after year?

+115.4% a year over 4 filed years; profitable in 4 of 4.

weight 45% of this tense · 93rd percentile among 323 sector filers · read for its customers

From the record

Purple Biotech Ltd.'s 4 filed years say what it did: revenue went from $100 thousand in fiscal 2017 to $1 million in fiscal 2020, up 115.4% a year; it rose in 3 of 3 years; it never fell from a peak; net income was positive in 4 of 4 of those years (its annual reports).

What it rests on

revenue growth over the filed span115.4%top 8% of its family
the share of years revenue rosetop 8% of its family
the share of filed years with a profittop 3% of its family
the deepest fall from a revenue peak0.0%top 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

0.3/10

How has it treated the people who own it?

SI estimate 0.3/10, confidence 35 of 100 (one part).

weight 33% of this tense · 3rd percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 3% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Purple Biotech Ltd.'s shareholder treatment is put at 0.3 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 3% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

3.9/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

1.7/10

Is it financially healthy right now?

ROE -274%: lost 274¢ per shareholder dollar. Leverage 45%: owes 45¢ per asset dollar.

weight 45% of this tense · 17th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Purple Biotech Ltd. lost about 274 cents for every dollar of shareholders' money. Leverage: it owed about 45 cents per dollar of assets, and net share issuance: its share count grew 58458.6% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 38% of its family
return on equitybottom 11% of its family
the share count against the year beforebottom 1% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

7.0/10

How strong is its position in its industry?

top 30% of 315 in its family; net margin 2807.4%.

weight 22% of this tense · 70th percentile among 315 sector filers · read for its customers

From the record

Purple Biotech Ltd.'s standing among 315 graded names in its industry family: revenue of $1 million in fiscal 2020 ranks in the bottom 22% by size; a net margin of 2807.4% ranks in the top 1%; revenue growth of 115.4% a year over the last 3 filed years ranks in the top 12% (its annual reports).

What it rests on

revenue against the family$1.0Mbottom 22% of its family
net margin2807.4%top 1% of its family
three-year revenue growth115.4%top 12% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 33% of this tense · 50th percentile among 371 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 7 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one.
What the record cannot read: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 7 months and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned: family median, 371 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Purple Biotech Ltd.'s leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 7 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

4.4/1040% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

SI estimate

6.7/10

How much room does it have to grow?

SI estimate 6.7/10, confidence 35 of 100 (one part).

weight 33% of this tense · 67th percentile among 479 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, cash less debt against assets, which ranks in the top 33% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
What the record cannot read: The record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
How it was reasoned: one part: cash less debt against assets, the one part on file, ranked among 479 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Purple Biotech Ltd.'s room to expand is put at 6.7 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the top 33% of 479 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.

Growth drivers

as filed

3.0/10

What could actually drive growth from here?

bottom 30% of 306 in its family for growth drivers.

weight 45% of this tense · 30th percentile among 306 sector filers · read for its customers

From the record

Purple Biotech Ltd.'s growth drivers, from the filed years to fiscal 2020: revenue grew 115.4% a year over the last three filed years against 115.4% over all 4, speeding up (top 40% of its family); the newest year grew 0% (bottom 38%); research spending grew -38.8% a year (bottom 8%); capital spending grew -59.8% a year (bottom 14%) (its annual reports). Purple Biotech Ltd. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span+0.0 points a yeartop 40% of its family
the newest year's revenue growth0.0%bottom 38% of its family
three-year growth of research spending-38.8%bottom 8% of its family
three-year growth of capital spending-59.8%bottom 14% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

3.9/10

Did its newest year beat what its own record pointed to?

bottom 39% of 233 in its family for expectations against reality.

weight 22% of this tense · 39th percentile among 233 sector filers · read for its shareholders

From the record

Purple Biotech Ltd.'s newest year against its own record: revenue of $1 million in fiscal 2020 came in 68.4% below the $3 million its prior three years' pace pointed to (bottom 13% of its family); net income of $28 million against a prior three-year average of $8 million (top 5%); a net margin of more than its whole revenue against more than its whole revenue before (bottom 11%) (its annual reports).

What it rests on

revenue against the prior three years' pace-68.4%bottom 13% of its family
net income against the prior three years' average+246%top 5% of its family
net margin against its prior averagedown more than 100 pointsbottom 11% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton PPBT · research, not advice